Full text is available at the source.
Abstract
RNA-targeting CRISPR systems may provide a new approach to treating chronic hepatitis B virus (HBV) infections.
- Chronic HBV infection is a significant global health issue with no current curative treatment.
- Synthetic guide RNA (gRNA)/Cas13d ribonucleoproteins (RNPs) were evaluated for their ability to target and degrade HBV RNA.
- The study explored the potential antiviral effects of combining RNA-targeting RNPs with DNA-targeting RNPs.
- Direct degradation of viral transcripts without causing genomic breaks is a key advantage of RNA-targeting CRISPR systems.
Simplified